Long-term Survivors of Childhood Brain Tumors: Impact on General Health and Quality of Life
- 543 Downloads
Purpose of Review
We review and summarize the key issues affecting general health and quality of life (QOL) of pediatric long-term survivors of brain tumors.
Long-term survivors of brain tumors are at risk of considerable late morbidity and mortality. Lengthening survival in brain tumors has highlighted the deep impact of tumor and its treatment on the physical, psychological, functional, and social health and QOL of these survivors. Evolution in tumor therapy including surgery, radiotherapy, and systemic therapies, etc., has the potential to mitigate this impact to some extent.
Sensitization of health staff, policy makers, and the primary designers of clinical trials towards integration of QOL end points while measuring survival in brain tumor patients is the need of the hour. New developments in tumor therapeutics must not only provide quantitative gain but also improve the quality of survival in these long-term survivors. While majority of the issues presented pertain to survivorship in pediatric brain tumor population, similar challenges are likely to exist in young adults surviving brain tumors as well.
KeywordsBrain tumors Long-term survivors Cancer survivors Childhood brain tumors
Compliance with Ethical Standards
Conflict of Interest
Priyamvada Gupta and Rakesh Jalali each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki Declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.•• Armstrong GT, Chen Y, Yasui Y, Leisenring W, Gibson TM, Mertens AC, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374(9):833–42. CCSS group studied late mortality in > 34,000 childhood cancer survivors including > 6,000 CNS patients, showing that 40% of deaths are due to health-related causes. Evolution in treatment over two decades directly reduced late mortality by lowering the therapeutic exposure. PubMedPubMedCentralCrossRefGoogle Scholar
- 20.• Gunn ME, Lähdesmäki T, Malila N, Arola M, Grönroos M, Matomäki J, et al. Late morbidity in long-term survivors of childhood brain tumors: a nationwide registry-based study in Finland. Neuro-Oncology. 2015;17(5):747–56. The authors showed that risk of development of endocrinopathies, cognitive deficits, developmental disorders, and neurological diseases at > 5 years from cancer diagnosis is many times higher in childhood BTLS as compared to that in siblings. PubMedCrossRefGoogle Scholar
- 23.• Brinkman TM, Bass JK, Li Z, Ness KK, Gajjar A, Pappo AS, et al. Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: results from the St. Jude Lifetime Cohort Study. Cancer. 2015;121(22):4053–61. Serious therapy-related hearing loss is seen in a third of childhood BTLS, with significant adverse impact on their education, employment, and independent living. PubMedPubMedCentralCrossRefGoogle Scholar
- 26.• Sterkenburg AS, Hoffmann A, Gebhardt U, Warmuth-Metz M, Daubenbüchel AMM, Müller HL. Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. Neuro-Oncology. 2015;17(7):1029–38. Hypothalamic involvement in craniopharyngioma may cause severe long-term obesity, reduced 20-year OS, and worse long-term QOL in survivors. PubMedPubMedCentralCrossRefGoogle Scholar
- 33.Fox SW, Lyon D, Farace E. Symptom clusters in patients with high-grade glioma. J Nurs Scholarsh an Off Publ Sigma Theta Tau Int Honor Soc Nurs. 2007;39(1):61–7.Google Scholar
- 36.• Brinkman TM, Liptak CC, Delaney BL, Chordas CA, Muriel AC, Manley PE. Suicide ideation in pediatric and adult survivors of childhood brain tumors. J Neuro-Oncol. 2013;113(3):425–32. Nearly 12% of BTLS reported suicide ideation, especially those with previous history of seizures or depression CrossRefGoogle Scholar
- 38.•• Hobbie WL, Ogle S, Reilly M, Barakat L, Lucas MS, Ginsberg JP, et al. Adolescent and young adult survivors of childhood brain tumors: life after treatment in their own words. Cancer Nurs. 2017;39(2):134–43. The authors provide a unique perspective of life after brain tumor treatment in the survivors’ own words, highlighting the long-term impact of therapy-related morbidity. CrossRefGoogle Scholar
- 43.Lorenzi M, McMillan AJ, Siegel LS, Zumbo BD, Glickman V, Spinelli JJ, et al. Educational outcomes among survivors of childhood cancer in British Columbia, Canada: report of the Childhood/Adolescent/Young Adult Cancer Survivors (CAYACS) Program. Cancer. 2009;115(10):2234–45.PubMedCrossRefGoogle Scholar
- 46.de Boer AGEM, Verbeek JHAM, van Dijk FJH. Adult survivors of childhood cancer and unemployment. Cancer 2006;107(1):1–11.Google Scholar
- 51.• Chevignard M, Câmara-costa H, Doz F, Dellatolas G. Core deficits and quality of survival after childhood medulloblastoma: a review. Neuro-Oncology Pract. 2017;4(2):82–97. An insightful review of the long-term dysfunction and its causative factors in childhood medulloblastoma survivors Google Scholar
- 55.van Dijk EM, van Dulmen-den Broeder E, Kaspers GJL, van Dam EWCM, Braam KI, Huisman J. Psychosexual functioning of childhood cancer survivors. Psychooncology 2008;17(5):506–511.Google Scholar
- 63.Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102(14):1083–95.Google Scholar
- 64.•• Tallen G, Resch A, Calaminus G, Wiener A, Leiss U, Pletschko T, et al. Strategies to improve the quality of survival for childhood brain tumour survivors. Eur J Paediatr Neurol. 2015;19(6):619–39. The authors have studied the QOL issues in European childhood BTLS in detail and provided recommendations covering all the aspects of treatment to improve long-term QOL of survivors. PubMedCrossRefGoogle Scholar
- 77.Hocking MC, Hobbie WL, Deatrick JA, Hardie TL, Barakat LP. Family functioning mediates the association between neurocognitive functioning and health-related quality of life in young adult survivors of childhood brain tumors. J Adolesc Young Adult Oncol. 2015;4(1):18–25.PubMedPubMedCentralCrossRefGoogle Scholar
- 81.Georgiadi M, Kourkoutas EE. Supporting pupils with cancer on their return to school: a case study report of a reintegration program. Procedia - Soc Behav Sci. 2010;5(2):1273–7.Google Scholar
- 87.• Jalali R, Gupta T, Goda JS, Goswami S, Shah N, Dutta D, et al. Efficacy of stereotactic conformal radiotherapy vs conventional radiotherapy on benign and low-grade brain tumors: a randomized clinical trial. JAMA Oncol. 2017;3(10):1368–76. Level 1 evidence has been generated with this RCT for benefit of modern high-precision conformal RT over conventional RT to preserve neurocognitive and endocrine functions in pediatric benign/low-grade CNS tumors. PubMedCrossRefGoogle Scholar
- 93.• Gondi V, Yock TI, Mehta MP. Proton therapy for paediatric CNS tumours - improving treatment-related outcomes. Nat Rev Neurol. 2016;12(6):334–45. The authors have provided a balanced review of all the evidence of the use of proton therapy in childhood CNS tumors, its benefit in limiting toxicities justifying the high costs. PubMedCrossRefGoogle Scholar
- 96.Igaki H, Sakumi A, Mukasa A, Saito K, Kunimatsu A, Masutani Y, et al. Corticospinal tract-sparing intensity-modulated radiotherapy treatment planning. Reports Pract Oncol Radiother J Gt Cancer Cent Pozn Polish Soc Radiat Oncol. 2014;19(5):310–6.Google Scholar
- 97.• Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131(6):821–31. Molecular-based risk stratification in medulloblastoma is the foundation of therapy de-escalation and personalized treatment for these patients PubMedPubMedCentralCrossRefGoogle Scholar
- 98.Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016;17(4):484–95.PubMedPubMedCentralCrossRefGoogle Scholar